Business Context and Reporting Period
This Form 10-Q covers Schering-Plough Corporation for the quarterly and nine-month periods ended September 30, 1999. The company is a worldwide research-based pharmaceutical firm engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products. Effective January 1, 1999, the company reorganized its internal structure to report as a single segment, consolidating its previous pharmaceuticals and healthcare units.
Key Financial Metrics
| Metric (in millions) | Q3 1999 | Q3 1998 | 9M 1999 | 9M 1998 |
|---|---|---|---|---|
| Net Sales | $2,236 | $1,986 | $6,873 | $6,018 |
| Net Income | $518 | $432 | $1,604 | $1,337 |
| Diluted EPS | $0.35 | $0.29 | $1.08 | $0.90 |
| Operating Cash Flow (9M) | $1,324 (vs $1,528 in 1998) | |||
| Cash & Equivalents (End of Period) | $1,665 | |||
| Total Debt (Short-term + Long-term) | $1,705 ($695 current + $1,010 long-term) | |||
| Cost of Sales Margin | 19.6% | 19.9% | 19.5% | 19.9% |
| R&D as % of Sales | 13.6% | 12.9% | 12.6% | 12.3% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% in Q3 and 14% for the nine-month period compared to 1998. Growth was driven by the Allergy & Respiratory category (up 13% Q3, 15% 9M) and Anti-infectives & Anticancer (up 29% Q3, 38% 9M).
- Profitability: Net income rose 20% in Q3 and 20% for the nine-month period. Diluted earnings per share increased 21% in Q3 and 20% year-to-date.
- Expense Trends: Selling, general, and administrative expenses as a percentage of sales decreased (36.4% in Q3 1999 vs. 38.4% in 1998). R&D spending increased 19% in Q3 and 16% for the nine months, reflecting funding for internal research and collaborations.
- Cash Flow: Operating cash flow for the nine months decreased by $204 million to $1,324 million, primarily due to timing of collections (increased accounts receivable) and strategic stockpiling of inventory.
- Shareholder Returns: The company repurchased $475 million of common shares in the first nine months of 1999 (vs. $109 million in 1998) and increased the quarterly dividend by 14% to $0.125 per share.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects R&D spending for the full year 1999 to increase more than 15% over the prior year. The company anticipates continued strong market growth for the CLARITIN brand and REBETRON Combination Therapy.
- Legal Proceedings:
- Antitrust Actions: The company is a defendant in over 160 antitrust actions alleging price-fixing. While a federal class action was settled for $22 million, state cases remain pending. Management believes these actions are without merit.
- Patent Litigation: Multiple generic manufacturers (Geneva, Copley, Teva, Novex, Zenith) have filed suits challenging patents for CLARITIN and CLARITIN Syrup. The company is vigorously defending these patents, which are material to its business.
- Arbitration: An ongoing dispute with Biogen, Inc. regarding royalty calculations for REBETRON Combination Therapy.
- Year 2000 (Y2K) Readiness: The company estimates a maximum project cost of $95 million, with $62 million incurred as of September 30, 1999. Remediation of critical IT systems is 100% complete; non-IT systems are 99% complete. Management believes Y2K will not materially affect internal operations but acknowledges risks from third-party disruptions.
- Market Risks: Exposure to foreign currency exchange rates and interest rates is not considered material. However, the company faces risks from government-mandated cost containment, generic competition, and regulatory approval delays.
Investor Verification Checklist
- Verify the status of pending antitrust litigation and potential liability exposure beyond accrued amounts.
- Monitor the outcome of patent infringement suits regarding CLARITIN, as a loss could significantly impact future revenue.
- Confirm the completion of Year 2000 remediation for non-critical non-IT systems and assess third-party vendor readiness.
- Review the sustainability of R&D spending increases and the pipeline of new product approvals.
- Assess the impact of generic competition on cardiovascular products (IMDUR, NORMODYNE) and future sales trends.